Xenotransplantation technology developer eGenesis took its total funding to $263m in a series C round backed by Bayer and Fresenius Medical Care.

US-based gene-editing technology developer eGenesis closed a $125m series C round yesterday that included pharmaceuticals and chemicals producer Bayer and kidney dialysis centre operator Fresenius Medical Care. Bayer subsidiary Leaps by Bayer and Fresnius unit Fresenius Medical Care Ventures were joined by fellow existing investors Arch Venture Partners, Wellington Partners, Khosla Ventures and Alta Partners.…

The rest of this content is only accessible to Corporate Venturing: News, Data, and Events - Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.